Predictive value of asymmetric dimethylarginine and C-reactive protein for the risk of developing metabolic syndrome in middle-aged men ☆

[1]  T. Kawada,et al.  Asymmetric dimethylarginine is related to the predicted stroke risk in middle-aged Japanese men , 2014, Journal of the Neurological Sciences.

[2]  Bertram L Kasiske,et al.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. , 2011, Kidney international.

[3]  A. Contreras,et al.  Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. , 2011, Nitric oxide : biology and chemistry.

[4]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[5]  Yasuhiko Tomino,et al.  Revised equations for estimated GFR from serum creatinine in Japan. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  E. Benjamin,et al.  Plasma Asymmetric Dimethylarginine and Incidence of Cardiovascular Disease and Death in the Community , 2009, Circulation.

[7]  Guogang Zhang,et al.  Asymmetric dimethylarginine induces TNF-alpha production via ROS/NF-kappaB dependent pathway in human monocytic cells and the inhibitory effect of reinioside C. , 2008, Vascular pharmacology.

[8]  G. Can,et al.  Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. , 2008, Metabolism: clinical and experimental.

[9]  Victor M Montori,et al.  Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. , 2007, Journal of the American College of Cardiology.

[10]  G. Hotamisligil,et al.  Inflammation and metabolic disorders , 2006, Nature.

[11]  Wenjiang J. Fu,et al.  Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. , 2006, The Journal of nutritional biochemistry.

[12]  E. Yeh,et al.  Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.

[13]  A. Madan,et al.  Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. , 2004, Endocrinology.

[14]  T. Münzel,et al.  ADMA and oxidative stress. , 2003, Atherosclerosis. Supplements.

[15]  N. Sattar,et al.  Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. , 2002, Diabetes care.

[16]  G. Russo.  Vasoactive substances Nitric oxide and endothelial dysfunction in atherosclerosis , 2002 .

[17]  N. Rifai,et al.  Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. , 2000, Clinical chemistry.

[18]  R. Henry,et al.  The expression of TNF alpha by human muscle. Relationship to insulin resistance. , 1996, The Journal of clinical investigation.

[19]  B. Spiegelman,et al.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. , 1995, The Journal of clinical investigation.

[20]  R. Simsolo,et al.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. , 1995, The Journal of clinical investigation.

[21]  B. Hazenberg,et al.  The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. , 1988, Biochemical and biophysical research communications.

[22]  N Rifai,et al.  Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. , 2001, Clinical chemistry.

[23]  S. Okuda,et al.  Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. , 1997, Hypertension.